High-Intensity Aphasia Therapy Is Cost-Effective in People With Poststroke Aphasia: Evidence From the COMPARE Trial
Stroke · 2024
DOI: 10.1161/strokeaha.123.045183 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Stroke, 2024. Verfasst von Joosup Kim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia (J.K., D.A. Cadilhac…. Hauptthemen laut MEDLINE: Stroke Rehabilitation, Aphasia, Stroke. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Evidence from systematic reviews confirms that speech and language interventions for people with aphasia during the chronic phase after stroke (>6 months) improve word retrieval, functional communication, and communication-related quality of life. However, there is limited evidence of their cost-effectiveness. We aimed to estimate the cost per quality-adjusted life year gained from 2 speech and language therapies compared with usual care in people with aphasia during the chronic phase (median, 2.9 years) after stroke. METHODS: A 3-arm, randomized controlled trial compared constraint-induced aphasia therapy plus (CIAT-Plus) and multimodality aphasia therapy (M-MAT) with usual care in 216 people with chronic aphasia. Participants were administered a standardized questionnaire before intervention and at 12 weeks after the 2-week intervention/control period to ascertain health service utilization, employment changes, and informal caregiver burden. Unit prices from Australian sources were used to estimate costs in 2020. Quality-adjusted life years were estimated using responses to the EuroQol-5 Dimension-3 Level questionnaire. To test uncertainty around the differences in costs and outcomes between groups, bootstrapping was used with the cohorts resampled 1000 times. RESULTS: Overall 201/216 participants were included (mean age, 63 years, 29% moderate or severe aphasia, 61 usual care, 70 CIAT-Plus, 70 M-MAT). There were no statistically significant differences in mean total costs ($13 797 usual care, $17 478 CIAT-Plus, $11 113 M-MAT) and quality-adjusted life years (0.19 usual care, 0.20 CIAT-Plus, 0.20 M-MAT) between groups. In bootstrapped analysis of CIAT-Plus, 21.5% of iterations were likely to result in better outcomes and be cost saving (dominant) compared with usual care. In contrast, 72.4% of iterations were more favorable for M-MAT than usual care. CONCLUSIONS: We observed that both treatments, but especially M-MAT, may result in better outcomes at an acceptable additional cost, or potentially with cost savings. These findings are relevant in advocating for the use of these therapies for chronic aphasia after stroke.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia (J.K., D.A. Cadilhac).
- Stroke Division, Florey Institute of Neuroscience and Mental Health, Heidelberg, Victoria, Australia (J.K., D.A. Cadilhac).
- School of Allied Health, Human Services and Sport (M.L.R., J.E.P., A.M., M.C., C.W.), Melbourne, Victoria, Australia.
- Centre of Research Excellence in Aphasia Recovery and Rehabilitation, La Trobe University (M.L.R., J.E.P., M.H., A.F., M.C., C.W., D.A. Cadilhac), Melbourne, Victoria, Australia.
- School of Psychological Sciences, Macquarie University, Sydney, New South Wales, Australia (L.N.).
- Queensland Aphasia Research Centre, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Australia (D.A. Copland).
ORCID-Profile: Joosup Kim, Miranda L Rose, John E Pierce, Lyndsey Nickels, David A Copland, Leanne Togher, Erin Godecke, Tapan Rai, Melanie Hurley, Abby Foster, Marcella Carragher, Dominique A Cadilhac
Zitieren
APA
Kim, J., Rose, M. L., Pierce, J. E., Nickels, L., Copland, D. A., Togher, L., Godecke, E., Meinzer, M., Rai, T., Hurley, M., Foster, A., Carragher, M., Wilcox, C., & Cadilhac, D. A. (2024). High-Intensity Aphasia Therapy Is Cost-Effective in People With Poststroke Aphasia: Evidence From the COMPARE Trial. Stroke. https://doi.org/10.1161/strokeaha.123.045183
Vancouver
Kim J, Rose ML, Pierce JE, Nickels L, Copland DA, Togher L, et al. High-Intensity Aphasia Therapy Is Cost-Effective in People With Poststroke Aphasia: Evidence From the COMPARE Trial. Stroke. 2024. doi:10.1161/strokeaha.123.045183
BibTeX
@article{Kim2024,
author = {Kim, Joosup and Rose, Miranda L and Pierce, John E and Nickels, Lyndsey and Copland, David A and Togher, Leanne and Godecke, Erin and Meinzer, Marcus and Rai, Tapan and Hurley, Melanie and Foster, Abby and Carragher, Marcella and Wilcox, Cassie and Cadilhac, Dominique A},
title = {High-Intensity Aphasia Therapy Is Cost-Effective in People With Poststroke Aphasia: Evidence From the COMPARE Trial},
journal = {Stroke},
year = {2024},
doi = {10.1161/strokeaha.123.045183}
}
EUVIMED